Novel application of human-derived fibroblast growth factor with long-acting mutations

A technology to source fibroblasts and growth factors, applied in the direction of fibroblast growth factors, growth factors/inducing factors, medical preparations of non-active ingredients, etc., can solve the problems of non-alcoholic steatohepatitis and achieve improvement of steatosis degree, improving the degree of liver damage, and improving the degree of hepatic lobular inflammation

Inactive Publication Date: 2018-10-09
TASLY BIOPHARMACEUTICALS CO LTD
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Liposaccharin can regulate blood sugar, lower blood triglycerides and regulate overall cholesterol, but there is no report on the use of liposaccharin in the treatment of non-alcoholic steatohepatitis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel application of human-derived fibroblast growth factor with long-acting mutations
  • Novel application of human-derived fibroblast growth factor with long-acting mutations

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Example 1: Preparation of Water Needle

[0021] 1. Composition: liposaccharin protein (10mg / mL concentration), histidine (pharmaceutical grade, 10mg / mL concentration), citric acid-sodium citrate buffer (20mM sodium citrate-citric acid, 100mMNaCl, pH5.5±0.1).

[0022] 2. Preparation method:

[0023] 1) The concentration is 12.5mg / mL liposaccharin protein stock solution, the buffer system is citric acid-sodium citrate, adjust the pH to 5.5±0.1, and set aside;

[0024] 2) The concentration is 50 mg / mL histidine mother solution, the buffer system is citric acid-sodium citrate buffer, adjust the pH to pH 5.5±0.1, and set aside;

[0025] 3) The adipoglycoside protein stock solution in step 1) and the histidine mother solution in step 2) are mixed according to the volume ratio of 4:1, and filled into 2mL vials with the specification of 500 μL / cartridge.

experiment example 1

[0026] Experimental Example 1: Therapeutic effect of liposaccharin on a methionine and choline-deficient diet (MCD diet)-induced non-alcoholic steatohepatitis (NASH) mouse model within an effective dose range.

[0027] In this experiment, methionine choline-deficient diet (MCD) was used to induce mouse NASH model, mainly because the application of this kind of feed has a history of more than 40 years, its production process has become more mature and its triggering characterization has been verified by many parties. Its quickness (it can induce NASH-related symptoms in about 4 weeks) and effectiveness (the induced symptoms are very similar to those of human NASH).

[0028] 1. Experimental method:

[0029] Eight-week-old C57BL male mice were fed with methionine and choline deficiency (MCD) feed after two weeks of adaptive feeding. After two weeks of MCD feed feeding, they were randomly divided into four groups according to animal weight, which were solvent group, FGF21 group, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to novel application of a human-derived fibroblast growth factor with long-acting mutations. The human-derived fibroblast growth factor with long-acting mutations is lipolysaccharide, and the novel application is the application of the human-derived fibroblast growth factor in preparing a medicine for treating non-alcoholic steatohepatitis.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to the application of a long-acting mutant human fibroblast growth factor-21 in the medicine for treating nonalcoholic steatohepatitis. Background technique [0002] Non-alcoholic fatty liver disease (NAFLD), also known as non-alcoholic fatty liver (non-alcoholic fatty liver), is caused by a variety of reasons. It is characterized by denaturation and triglyceride (triglyceride, TG) accumulation (hepatic tissue fat content exceeds 5% of liver wet volume, or more than 1 / 3 of liver cells are fatty in histology), pathological changes and alcoholic liver disease (Alcoholic liver disease, ALD) similar, but no history of excessive alcohol consumption (ethanol equivalent amount <140g / week for men, <70g / week for women) and other clinical and pathological syndromes with clear liver damage factors. [0003] The disease spectrum of NAFLD includes non-alcoholic fatty liver (NAFL), n...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/18A61P1/16
CPCA61K38/1825A61P1/16C07K14/50A61K47/60A61K38/00
Inventor 李剑韩君马晓慧太平王根辈曹小丹黄瑞晶金永杰李静陈晨贾国勇王媛媛
Owner TASLY BIOPHARMACEUTICALS CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap